InBioGen Co Deferred Tax Liabilities
The Deferred Tax Liabilities of InBioGen Co (101140.KS) as of Oct 20, 2026 is 16.95 B KRW.
Get this data via API
Financial Data API
Deferred Tax Liabilities
16.95 BKRW
Last updated:
Deferred Tax Liabilities of InBioGen Co is 2021 16.95 B KRW. Deferred Tax Liabilities of InBioGen Co was 2020 - KRW. It decreases by % lower compared to the previous year.
The InBioGen Co Deferred Tax Liabilities history
| YEAR | Deferred Tax Liabilities | YoY |
|---|---|---|
| 16.95 BKRW | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
InBioGen Co Stock analysis
What does InBioGen Co do? INBIOGEN CO., Ltd. generates revenue through four distinct business segments, leveraging its manufacturing and sales capabilities across diverse markets. The Kiosk Business segment operates unmanned payment machines within restaurants, karaoke rooms, and personal computer rooms, providing automated transaction solutions for these specific venues. This segment capitalizes on the demand for efficient, contactless payment infrastructure in high-traffic entertainment and dining areas.
The Footwear Business segment focuses on the sale of children's shoes and adult shoes, serving consumers seeking specific apparel categories. Complementing this, the Wood Pellet Business segment sells wood pellets and sawdust, addressing energy or industrial material needs. These two segments represent the core physical product offerings of the company, targeting different consumer and industrial bases respectively.
Additionally, the Other Business segment engages in online and offline education to foster human resources in the FinTech service, platform business, and block chain industry. This educational arm targets individuals and professionals seeking skills in emerging financial technologies. By combining physical goods with specialized training services, INBIOGEN CO., Ltd. diversifies its income streams across technology, retail, energy, and education sectors. InBioGen Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about InBioGen Co stock
Deferred Tax Liabilities of InBioGen Co is 16.95 B KRW in 2021.
On Eulerpool you can find the complete historical development of Deferred Tax Liabilities InBioGen Co since 2006 – with annual values, charts, and detailed analysis.
Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.
Deferred Tax Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's InBioGen Co historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Balance Sheet — InBioGen Co
Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets
All Key Metrics — InBioGen Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth